CD274 and head and neck squamous cell carcinoma: Regarding PFS for first-line treatment (Figures 9A, C), in R/M HNSCC patients with PD-L1 expression ≥1%, only pembrolizumab plus chemotherapy (HR=0.82, 95% CI: 0.67-1.00) showed a statistically significant extension of PFS compared to SOC.